Diagnostic Performance of a Novel Ferumoxytol-Enhanced Magnetic Resonance Angiography/ Venography on Panvascular Disease

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

February 23, 2024

Primary Completion Date

January 30, 2025

Study Completion Date

January 30, 2025

Conditions
Panvascular Disease
Interventions
DIAGNOSTIC_TEST

Ferumoxytol Enhanced Magnetic Resonance Angiography( FE-MRA);Coronary/Renal /Lower artery Arteriography

When the patient is suspected with multisite artery disease, FE-MRA and angiography will be performed according to the patient's clinical manifestation. For example, when the patient is suspected with coronary artery disease, coronary FE-MRA and angiography will be performed; when the patient is suspected with renal artery stenosis, renal artery FE-MRA and angiography will be performed; and when the patient is suspected with the lower extremity artery occlusion, the lower extremity artery FE-MRA and angiography will be performed.

DIAGNOSTIC_TEST

Ferumoxytol Enhanced Magnetic Resonance Venography( FE-MRV), Computed Tomography Pulmonary Angiography, Ultrasound for Lower Extremity Deep Vein.

When the patient is suspected with venous thromboembolism, the lower extremity vein FE-MRV, pulmonary FE-MRA and ultrasound for lower extremity deep vein as well as computed tomography pulmonary angiography will be taken to ensure whether the patient with thrombus or not.

Trial Locations (1)

210000

RECRUITING

First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER